A Post-Authorization Safety Study of the Use of Intravenous Telavancin

• Research type

  Research Study

• Full title

  A Post-Authorization Safety Study of the Use of Intravenous Telavancin (VIBATIV®) in the Clinical Setting

• IRAS ID

  181568

• Contact name

  Karen O'Hanlon

• Contact email

  karen.o'hanlon@clinigengroup.com

• Sponsor organisation

  Clinigen Healthcare Ltd

• Duration of Study in the UK

  3 years, 0 months, 31 days

• Research summary

  This study is designed to collect information on actual clinical usage of telavancin and to ensure that any safety concerns associated with telavancin are appropriately documented and followed up.

• REC name

  East of Scotland Research Ethics Service REC 2

• REC reference

  16/ES/0136

• Date of REC Opinion

  21 Oct 2016

• REC opinion

  Favourable Opinion